Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 12/20 | 0.56 |
| ▸ | GIPR | P48546 | 12/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | IDH1 | O75874 | 1/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.45 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18674589 | 0.82 | GCGR (0.63) | GCGRGIPR | |
| SCHEMBL18674659 | 0.79 | KMT2A (0.53) | GCGRGIPRNPC1RAB9AKDM4E | |
| SCHEMBL2649088 | 0.77 | GCGR (0.81) | GCGRGIPRPOLBMEN1KMT2A | |
| SCHEMBL2665865 | 0.77 | GCGR (0.81) | GCGRGIPR | |
| SCHEMBL2647280 | 0.76 | GCGR (0.88) | GCGRGIPR | |
| SCHEMBL1744789 | 0.76 | KMT2A (0.54) | NPC1RAB9AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL5162963 | 0.75 | GCGR (0.49) | GCGRGIPRNPC1RAB9APOLB | |
| SCHEMBL2648168 | 0.75 | GCGR (0.79) | GCGRGIPR | |
| SCHEMBL9071163 | 0.75 | GCGR (0.61) | GCGRGIPR | |
| SCHEMBL2647095 | 0.74 | GCGR (0.77) | GCGRGIPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1833807-A1 | UBIQUITIN LIGASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2007-09-19 | — | — | EP | disclosed |
| US-20060160869-A1 | Ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | disclosed |
| WO-2006074262-A1 | UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006074262-A1 | UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160869-A1 | Ubiquitin ligase inhibitors | MDM2, NEDD4, XIAP | GCGR 3931/4885GIPR 2282/4885NPC1 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.